Simpson Thacher Represents JPMorgan and Barclays’ Financing of Perrigo’s $4.5 Billion Acquisition of Omega Pharma Invest NV
11.14.14
This is only gets display when printing
The Firm is representing JPMorgan Chase Bank, N.A. and Barclays Bank plc in connection with the provision of committed financing to Perrigo Company plc (“Perrigo”) for its announced $4.5 billion acquisition of Omega Pharma Invest NV (“Omega”). The financing consists of a €1.75 billion 364-day bridge facility as well as term loan and revolving facilities backstopping Perrigo’s existing term loan facility and revolving facility.
Perrigo, headquartered in Ireland, is a global healthcare supplier that develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients. Omega is an over-the-counter healthcare company headquartered in Nazareth, Belgium with operations in 35 countries across Europe and selected emerging markets.
The Simpson Thacher team for the financing includes Patrick Ryan, Dan Kay and Katharine Thompson (Banking and Credit); John Ericson and Paul Bennett (Capital Markets); Ed Chung (M&A); David Rubinsky and Eric Wolf (Executive Compensation and Employee Benefits); Jacqueline Barbera (Tax); and Tim Mulvihill (Environmental).